Skip to content
Open access · CC-BY via OpenAlex

Cell-Based Therapies for Stroke: Promising Solution or Dead End? Mesenchymal Stem Cells and Comorbidities in Preclinical Stroke Research

Fernando Laso-García, Luke Diekhorst, Mari Carmen Gómez-de Frutos, Laura Otero‐Ortega, Blanca Fuentes, Gerardo Ruiz Ares, Exuperio Díez‐Tejedor, María Gutiérrez‐Fernández

Frontiers in Neurology · 2019 · ▲ 23 citations

Abstract

Stroke is a major health problem worldwide. It has been estimated that 90% of the population attributable risk of stroke is due to risk factors such as aging, hypertension, hyperglycemia, diabetes mellitus and obesity, among others. However, most animal models of stroke use predominantly healthy and young animals. These models ignore the main comorbidities associated with cerebrovascular disease, which could be one explanation for the unsuccessful bench-to-bedside translation of protective and regenerative strategies by not taking the patient's situation into account. This lack of success makes it important to incorporate comorbidities into animal models of stroke in order to study the effects of the various therapeutic strategies tested. Regarding cell therapy, the administration of stem cells in the acute and chronic phases has been shown to be safe and effective in experimental animal models of stroke. This review aims to show the results of studies with promising new therapeutic strategies such as mesenchymal stem cells, which are being tested in preclinical models of stroke associated with comorbidities and in elderly animals.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.3389/fneur.2019.00332
Canonical
link ↗
Fetched
2026-10-10 MST

Cite this

APA
Laso-García, F., Diekhorst, L., Frutos, M.C.G., Otero‐Ortega, L., Fuentes, B., Ares, G.R., Díez‐Tejedor, E., &amp; Gutiérrez‐Fernández, M. (2019). Cell-Based Therapies for Stroke: Promising Solution or Dead End? Mesenchymal Stem Cells and Comorbidities in Preclinical Stroke Research. <em>Frontiers in Neurology</em>. https://doi.org/10.3389/fneur.2019.00332
Vancouver
Laso-García F, Diekhorst L, Frutos MCG, Otero‐Ortega L, Fuentes B, Ares GR, et al. Cell-Based Therapies for Stroke: Promising Solution or Dead End? Mesenchymal Stem Cells and Comorbidities in Preclinical Stroke Research. Frontiers in Neurology. 2019. doi:10.3389/fneur.2019.00332.
BibTeX
@article{fernando2019CellBa, title = {Cell-Based Therapies for Stroke: Promising Solution or Dead End? Mesenchymal Stem Cells and Comorbidities in Preclinical Stroke Research}, author = {Fernando Laso-García and Luke Diekhorst and Mari Carmen Gómez-de Frutos and Laura Otero‐Ortega and Blanca Fuentes and Gerardo Ruiz Ares and Exuperio Díez‐Tejedor and María Gutiérrez‐Fernández}, journal = {Frontiers in Neurology}, year = {2019}, doi = {10.3389/fneur.2019.00332}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings